Economic impact of inflammatory bowel disease in Catalonia: a population-based analysis

dc.contributor.author
Brunet Mas, Eduard
dc.contributor.author
Garcia Sagué, Belen
dc.contributor.author
Vela, Emli
dc.contributor.author
Melcarne, Luigi
dc.contributor.author
Llovet, Laura Patricia
dc.contributor.author
Pontes García, Caridad
dc.contributor.author
García Iglesias, Pilar
dc.contributor.author
Puy, Anna
dc.contributor.author
Lario, Sergio
dc.contributor.author
Ramirez Lazaro, Maria Jose
dc.contributor.author
Villoria, Albert
dc.contributor.author
Burisch, Johan
dc.contributor.author
Kaplan, Gilaad G.
dc.contributor.author
Calvet, Xavier
dc.date.issued
2024-03-05T12:29:21Z
dc.date.issued
2024-03-05T12:29:21Z
dc.date.issued
2024-02-14
dc.date.issued
2024-02-26T12:48:41Z
dc.identifier
1756-2848
dc.identifier
https://hdl.handle.net/2445/208402
dc.identifier
38357537
dc.description.abstract
Background: Inflammatory bowel disease (IBD) has a major economic impact on healthcare costs.Objectives: The aim of this study was to evaluate the current healthcare expenditure associated with IBD in a population-wide study in Catalonia.Design: Retrospective observational study.Methods: All patients with IBD included in the Catalan Health Surveillance System (CHSS) were considered eligible. The CHSS compiles data on more than 7 million individuals in 2020 (34,823 with IBD). Data on the use of healthcare resources and its economic impact were extracted applying the International Classification of Diseases, 10th revision, Clinical Modification codes (ICD-10-CM codes). Health expenditure, comorbidities, and hospitalization were calculated according to the standard costs of each service provided by the Department of Health of the Catalan government. The data on the IBD population were compared with non-IBD population adjusted for age, sex, and income level. IBD costs were recorded separately for Crohn's disease (CD) and ulcerative colitis (UC).Results: Prevalence of comorbidities was higher in patients with IBD than in those without. The risk of hospitalization was twice as high in the IBD population. The overall healthcare expenditure on IBD patients amounted to 164Meuro. The pharmacy cost represents the 60%. The average annual per capita expenditure on IBD patients was more than 3.4-fold higher (IBD 4200euro, non-IBD 1200euro). Average costs of UC were 3400euro and 5700euro for CD.Conclusion: The risk of comorbidities was twice as high in patients with IBD and their use of healthcare resources was also higher than that of their non-IBD counterparts. Per capita healthcare expenditure was approximately 3.4 times higher in the population with IBD.Trial registration: The study was not previously registered. Economic impact of inflammatory bowel disease in CataloniaThe manuscript includes data of the most recent epidemiologic data about the high economic impact of IBD in Catalonia.
dc.format
12 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
SAGE Publications
dc.relation
Reproducció del document publicat a: https://doi.org/10.1177/17562848231222344
dc.relation
Therapeutic Advances in Gastroenterology, 2024, vol. 17
dc.relation
https://doi.org/10.1177/17562848231222344
dc.rights
cc by-nc (c) Brunet Mas, Eduard et al., 2024
dc.rights
http://creativecommons.org/licenses/by-nc/3.0/es/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject
Malalties inflamatòries intestinals
dc.subject
Catalunya
dc.subject
Inflammatory bowel diseases
dc.subject
Catalonia
dc.title
Economic impact of inflammatory bowel disease in Catalonia: a population-based analysis
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Fitxers en aquest element

FitxersGrandàriaFormatVisualització

No hi ha fitxers associats a aquest element.

Aquest element apareix en la col·lecció o col·leccions següent(s)